Prospective Study of Rituximab in Chemotherapy-Dependent Human Immunodeficiency Virus–Associated Multicentric Castleman's Disease: ANRS 117 CastlemaB Trial | Synapse
July 30, 2007Open Access
Prospective Study of Rituximab in Chemotherapy-Dependent Human Immunodeficiency Virus–Associated Multicentric Castleman's Disease: ANRS 117 CastlemaB Trial
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Rituximab was both effective and safe in HIV-infected patients with chemotherapy-dependent MCD.